Sign in Subscribe
Child health

Early Genetic Confirmation Crucial for Timely Insulin Initiation in Pediatric Patients with Maturity-Onset Diabetes of the Young

Strategic Insights

— 1 min read

Researchers at Wenzhou Medical University in the People's Republic of China have conducted a study to summarize the clinical phenotypes and genotypic characteristics of Chinese pediatric patients with maturity-onset diabetes of the young due to variants. The study included six children diagnosed with the condition between July 2020 and July 2024. The children had a median age of diabetes onset at 12.3 years, and their clinical features included pancreatic dysplasia, renal structural abnormalities, hypomagnesemia, hyperuricemia, elevated liver enzymes, and hyperlipidemia. Genetic testing identified a heterozygous exon: 1-9 deletion in one patient, while the other five had 17q12 microdeletions.

Key Takeaways:

  • The study included six pediatric patients with maturity-onset diabetes of the young due to variants, with a median age of diabetes onset at 12.3 years.
  • The clinical features of the patients included pancreatic dysplasia, renal structural abnormalities, hypomagnesemia, hyperuricemia, elevated liver enzymes, and hyperlipidemia.
  • Genetic testing identified a heterozygous exon: 1-9 deletion in one patient and 17q12 microdeletions in the other five patients.
  • Early genetic confirmation facilitated timely insulin initiation, guided targeted correction of electrolyte imbalances and metabolic disorders, and triggered proactive multi-organ monitoring for disease evolution.
  • Four children started insulin therapy at diagnosis, demonstrating no progressive decline in insulin secretion function and well-maintained insulin dependency.
  • Six children received oral magnesium supplementation, and blood magnesium levels persisted at the lower limit of normal without neuromuscular complications.
  • Combined therapy with urinary alkalinizing agents and uricosuric drugs effectively maintained serum urate levels.
  • Hepatoprotective therapy decreased liver enzymes in two cases.
  • The clinical phenotype of -MODY encompasses early-onset diabetes mellitus, pancreatic dysplasia, kidney disease, liver dysfunction, and genitourinary tract malformations, with refractory hypomagnesemia and hyperuricemia representing pathognomonic features.

Statistics:

  • Median age of diabetes onset in the study: 12.3 years.
  • Number of patients with pancreatic dysplasia: 6 (100%).
  • Number of patients with renal structural abnormalities: 6 (100%).
  • Number of patients with hypomagnesemia: 6 (100%).
  • Number of patients with hyperuricemia: 4 (67%).
  • Number of patients with elevated liver enzymes: 4 (67%).
  • Number of patients with hyperlipidemia: 3 (50%).
  • Number of patients with genitourinary tract malformations: 1 (17%).

Sources:

  • Maturity-onset diabetes of the young due to HNF1b variants (HNF1b-MODY): a 2-year follow-up study of six patients from a single diabetes center. Journal of Pediatric Endocrinology and Metabolism, 2025.
  • Journal of Pediatric Endocrinology and Metabolism, Walter De Gruyter Gmbh, Genthiner Strasse 13, D-10785 Berlin, Germany.

Read more